These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 24610297)
1. Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors. Curtis KK; Sarantopoulos J; Northfelt DW; Weiss GJ; Barnhart KM; Whisnant JK; Leuschner C; Alila H; Borad MJ; Ramanathan RK Cancer Chemother Pharmacol; 2014 May; 73(5):931-41. PubMed ID: 24610297 [TBL] [Abstract][Full Text] [Related]
2. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586 [TBL] [Abstract][Full Text] [Related]
3. A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors. Papadopoulos KP; Burris HA; Gordon M; Lee P; Sausville EA; Rosen PJ; Patnaik A; Cutler RE; Wang Z; Lee S; Jones SF; Infante JR Cancer Chemother Pharmacol; 2013 Oct; 72(4):861-8. PubMed ID: 23975329 [TBL] [Abstract][Full Text] [Related]
4. A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer. Chelariu-Raicu A; Nick A; Urban R; Gordinier M; Leuschner C; Bavisotto L; Molin GZD; Whisnant JK; Coleman RL Gynecol Oncol; 2021 Feb; 160(2):418-426. PubMed ID: 33243443 [TBL] [Abstract][Full Text] [Related]
6. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors. Engel J; Emons G; Pinski J; Schally AV Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891 [TBL] [Abstract][Full Text] [Related]
7. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822 [TBL] [Abstract][Full Text] [Related]
8. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Reid T; Oronsky B; Scicinski J; Scribner CL; Knox SJ; Ning S; Peehl DM; Korn R; Stirn M; Carter CA; Oronsky A; Taylor MJ; Fitch WL; Cabrales P; Kim MM; Burris HA; Lao CD; Abrouk NED; Fanger GR; Infante JR Lancet Oncol; 2015 Sep; 16(9):1133-1142. PubMed ID: 26296952 [TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631 [TBL] [Abstract][Full Text] [Related]
10. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459 [TBL] [Abstract][Full Text] [Related]
11. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. Hassan R; Blumenschein GR; Moore KN; Santin AD; Kindler HL; Nemunaitis JJ; Seward SM; Thomas A; Kim SK; Rajagopalan P; Walter AO; Laurent D; Childs BH; Sarapa N; Elbi C; Bendell JC J Clin Oncol; 2020 Jun; 38(16):1824-1835. PubMed ID: 32213105 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5). Emons G; Gorchev G; Harter P; Wimberger P; Stähle A; Hanker L; Hilpert F; Beckmann MW; Dall P; Gründker C; Sindermann H; Sehouli J Int J Gynecol Cancer; 2014 Feb; 24(2):260-5. PubMed ID: 24418927 [TBL] [Abstract][Full Text] [Related]
13. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Beg MS; Brenner AJ; Sachdev J; Borad M; Kang YK; Stoudemire J; Smith S; Bader AG; Kim S; Hong DS Invest New Drugs; 2017 Apr; 35(2):180-188. PubMed ID: 27917453 [TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors. Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545 [TBL] [Abstract][Full Text] [Related]
15. A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors. Pant S; Burris HA; Moore K; Bendell JC; Kurkjian C; Jones SF; Moreno O; Kuhn JG; McMeekin S; Infante JR Invest New Drugs; 2014 Feb; 32(1):87-93. PubMed ID: 23525756 [TBL] [Abstract][Full Text] [Related]
16. A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors. Chiorean EG; Sweeney C; Youssoufian H; Qin A; Dontabhaktuni A; Loizos N; Nippgen J; Amato R Cancer Chemother Pharmacol; 2014 Mar; 73(3):595-604. PubMed ID: 24452395 [TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors. Eder JP; Ryan DP; Appleman L; Zhu AX; Puchalski T; He X; Sonnichsen DS; Cooper M; Wright J; Clark JW; Supko JG Cancer Chemother Pharmacol; 2006 Jul; 58(1):107-16. PubMed ID: 16362299 [TBL] [Abstract][Full Text] [Related]
18. Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Gross ME; Leichman L; Lowe ES; Swaisland A; Agus DB Cancer Chemother Pharmacol; 2012 Jan; 69(1):273-80. PubMed ID: 22002543 [TBL] [Abstract][Full Text] [Related]
19. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy. Awada A; Piccart MJ; Jones SF; Peck RA; Gil T; Lebwohl D; Wu CY; Burris HA Cancer Chemother Pharmacol; 2009 Feb; 63(3):417-25. PubMed ID: 18446338 [TBL] [Abstract][Full Text] [Related]
20. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. Papadopoulos KP; Tabernero J; Markman B; Patnaik A; Tolcher AW; Baselga J; Shi W; Egile C; Ruiz-Soto R; Laird AD; Miles D; Lorusso PM Clin Cancer Res; 2014 May; 20(9):2445-56. PubMed ID: 24583798 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]